Furthermore, the targeted manipulation of key genes in CRC PDTOs, such as SMAD4 [45], NF-1 [46], MIEF2 [47], and RNF43 [48], has revealed their roles in mediating sensitivity or resistance to various therapeutic modalities, offering valuable insights for developing precision medicine strategies. The gene discussed is NF1; the disease is colorectal carcinoma.